Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent melanoma recurrence on ‘The Claman Countdown.’ #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #moderna #merck #cancer #vaccine #health #medicine #medical #melanoma #science #research #trial #biotech #technology #treatment #breakthrough #healthcare #innovation
Could a common medication help fight cancer? And what are American tourists saying after returning to Israel? In today's NEWSMAX Israel Update, Katrina Szish reports on new research from Israeli scientists who say the active ingredient in Viagra may help prevent cancer from spreading. The findings were based on mouse cancer models and decades of research, with clinical trials identified as a possible next step. Then, correspondent Jodie Cohen speaks with American visitors in Tel Aviv and Hostages Square, where tourists share their reactions to returning to Israel and reflect on the country's resilience and recovery.
Moderna CEO Stéphane Bancel joins ‘Mornings with Maria’ to discuss the company's landmark cancer vaccine partnership with Merck. Bancel details the promising Phase 3 melanoma trial results and outlines Moderna's latest financial growth outlook. #foxbusiness #morningswithmaria 0:03 – Moderna and Merck’s Personalized Cancer Vaccine Breakthrough 1:18 – Moderna Targets FDA Approval for Next Year 2:20 – Expanding mRNA Cancer Treatment Beyond Melanoma 5:21 – Moderna’s mRNA Push: Rare Diseases and a New Flu Vaccine 7:27 – Personalized Vaccine Costs, Manufacturing and Moderna’s Growth Outlook
Personalized vaccines could be around the corner thanks to decades of work by doctors like Michelle Wu. Her story and details on the new breakthrough on tonight's 11th Hour with Ali Velshi.
Last year, Health and Human Services Secretary RFK Jr. called mRNA vaccines for respiratory viruses unsafe for the public and the National Institutes of Health cut 22 programs totaling $500 million that targeted mRNA vaccine research for infectious diseases. Now, that same technology has succeeded in a clinical trial for treating skin cancer. CNN’s Meg Tirrell reports.
Moderna and Merck’s mRNA cancer vaccine showed positive results in a late-stage melanoma trial. The vaccine could be available as soon as next year if regulators approve it. Moderna shares surged as much as 160% following the results. Moderna developed the vaccine with Merck and tested it together with Keytruda, a common immunotherapy treatment for melanoma. This is the first successful late-stage trial for an mRNA cancer vaccine. The vaccine works by training a patient’s immune system to recognize and attack specific mutations in cancer cells. It is also the first study to show that adding another treatment to Keytruda worked better than Keytruda alone. Similar vaccines are being studied for lung, breast and pancreatic cancers.…
At 37, Alex was fit, healthy and working as a geneticist. Then he received a shocking diagnosis: stage 4 rectal cancer that had spread to his liver. In this episode of "Greta Wire," Greta Van Susteren sits down with Alex to hear how his symptoms began, why his cancer proved difficult to detect, and what it has been like undergoing radiation, chemotherapy, surgery and immunotherapy while still in his 30s. Alex also brings a unique perspective to his diagnosis. With a background in computational biology and statistical genetics, he has spent his career studying how genes influence disease — yet extensive testing has revealed no known genetic explanation for his own colorectal cancer. Now Alex is pursuing another option: an experimental…
AI:In a heartbreaking testament to the astronomical costs of modern medicine, Alex, a 37-year-old geneticist, is battling stage 4 rectal cancer that has metastasized to his liver despite having no detectable genetic predisposition. Even for someone whose career involves studying how genes influence disease, the medical reality has been devastating and unpredictable. As he navigates the grueling gauntlet of radiation, chemotherapy, surgery, and immunotherapy, Alex is turning to an experimental personalized cancer vaccine tailored specifically to his tumor mutations—a cutting-edge lifeline that carries a staggering $120,000 price tag. While the radical left focuses on social engineering and bureaucratic expansion, ordinary Americans are being…Open
- Alex Young, a 37-year-old UCLA genetics researcher, opens up about his stage 4 colorectal cancer diagnosis despite having no known family history or identifiable genetic risk. - Young describes months of warning signs, a false-negative blood test and delayed colonoscopy before doctors discover rectal cancer that has spread to his liver. - After chemotherapy, radiation and surgery, Young turns to next-generation immunotherapy while confronting the physical and emotional toll of fighting cancer at such a young age. - A GoFundMe campaign raises roughly $120,000 in a matter of hours, allowing Young to pursue a personalized cancer vaccine designed around the unique mutations in his tumor. - Young explains how personalized cancer vaccines…
AI:Alex Young, a 37-year-old UCLA genetics researcher with no prior family history of disease, has been forced into a desperate fight for survival after being diagnosed with stage 4 colorectal cancer that had already metastasized to his liver. Despite experiencing clear warning signs, Young was misled by a false-negative blood test and delayed medical procedures, highlighting the catastrophic failures within the current healthcare establishment. Following grueling rounds of chemotherapy, radiation, and surgery, he is now relying on a personalized immunotherapy vaccine targeting his specific tumor mutations—a high-cost lifeline made possible only through a rapid $120,000 GoFundMe campaign. His ordeal underscores the critical need for faster…Open
Dr. Jay Bhattacharya, Director of the National Institutes of Health and Acting Director of the Centers for Disease Control and Prevention, joins PragerU CEO Marissa Streit to discuss how the COVID-19 response became politicized, why public trust in science and public health institutions declined, and his efforts to remove DEI initiatives and other political priorities from the NIH. Dr. Bhattacharya reflects on the criticism he faced for opposing lockdowns and vaccine mandates during the pandemic and outlines his vision for returning the NIH to its core mission: funding world-class biomedical research that advances scientific innovation, improves health, and extends human longevity. Dr. Jay Bhattacharya joins Marissa Streit to discuss…
Researchers say the same technology used in COVID-19 vaccines could help prevent some of the deadliest cancers, such as melanoma and glioblastoma, from returning. NewsNation's Anna Kooiman reports.
